Lannett Company Inc
Change company Symbol lookup
Select an option...
LCI Lannett Company Inc
AVD American Vanguard Corp
VMVFX Vanguard Global Minimum Volatility Fund Investor Shares
IO ION Geophysical Corp
DNRCQ Denbury Resources Inc
MSFT Microsoft Corp
BCRX BioCryst Pharmaceuticals Inc
WMT WALMART STORES INC
ZN Zion Oil and Gas Inc
EBTC Enterprise Bancorp Inc
Go

Health Care : Pharmaceuticals | Small Cap Value
Company profile

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company's products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Company has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.

Price
Delayed
$6.15
Day's Change
-0.01 (-0.16%)
Bid
--
Ask
--
B/A Size
--
Day's High
6.19
Day's Low
6.05
Volume
(Average)

Today's volume of 41,896 shares is on pace to be in-line with LCI's 10-day average volume of 351,339 shares.

41,896

Display:

Providers:

UpdateCancel
6 providers
August 12, 2020
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter of Fiscal Year 2021 Results on August 17, 2020

Financials for First Quarter of Fiscal Year 2021 ended June 30, 2020 will be released August 14, 2020 NORTHVALE, NJ / ACCESSWIRE / August 12, 2020 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical...(Accesswire)

August 03, 2020
Lannett Announces Launch Of FDA Approved Levothyroxine Tablets

Lannett Company, Inc. (NYSE: LCI) today announced the launch of Cediprof, Inc.'s FDA approved Levothyroxine Sodium Tablets USP, under the companies recently announced interim exclusive supply and distribution agreement. (PR Newswire)

July 27, 2020
Lannett To Launch Levorphanol Tablets

Lannett Company, Inc. (NYSE: LCI) today announced that it will soon launch Levorphanol Tablets 2 mg, a partnered product. https://mma.prnewswire.com/media/199461/lannett_logo.jpg Lannett entered into an exclusive U.S. distribution agreement for...(PR Newswire)

July 23, 2020
Lannett Launches Mexiletine HCl Capsules

Lannett Company, Inc. (NYSE: LCI) today announced that it has launched Mexiletine Hydrochloride Capsules 150 mg, 200 mg and 250 mg, a partnered product. Mexiletine Hydrochloride Capsules is the AB-rated generic equivalent to Mexitil(R) Capsules of...(PR Newswire)

July 13, 2020
Lannett Announces Restructuring, Cost Reduction Initiatives

Lannett Company, Inc. (NYSE: LCI) today announced a restructuring and cost savings plan. The initiatives include consolidating the research and development (R&D) function into a single location in Philadelphia and lowering operating costs. The...(PR Newswire)

June 11, 2020
Lannett Provides Update On Clinical Advancement Of Biosimilar Insulin Glargine, Following FDA Meeting

Lannett Company, Inc. (NYSE: LCI) today said that representatives from the company spoke with and received guidance from the U.S. Food and Drug Administration (FDA) on the clinical advancement program of its biosimilar insulin glargine partnered...(PR Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.